Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-10-01 Epub Date: 2024-09-28 DOI:10.1177/13524585241275471
Alex Ocampo, Farhad Hatami, Jelena Čuklina, Gordon Graham, Habib Ganjgahi, Yang Sun, Wendy Su, Marie-Catherine Mousseau, Stephen Gardiner, Samantha C Pendleton, Piet Aarden, Bernd C Kieseier, Douglas L Arnold, Robert A Bermel, Dieter A Häring, Thomas E Nichols, Heinz Wiendl
{"title":"Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.","authors":"Alex Ocampo, Farhad Hatami, Jelena Čuklina, Gordon Graham, Habib Ganjgahi, Yang Sun, Wendy Su, Marie-Catherine Mousseau, Stephen Gardiner, Samantha C Pendleton, Piet Aarden, Bernd C Kieseier, Douglas L Arnold, Robert A Bermel, Dieter A Häring, Thomas E Nichols, Heinz Wiendl","doi":"10.1177/13524585241275471","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The long-term disease trajectory of people living with multiple sclerosis (MS) can be improved by initiating efficacious treatment early. More quantitative evidence is needed on factors that affect a patient's risk of disability worsening or possibility of improvement to inform timely treatment decisions.</p><p><strong>Methods: </strong>We developed a multistate model to quantify the influence of demographic, clinical, and imaging factors on disability worsening and disability improvement simultaneously across the disability spectrum as measured by the Expanded Disability Status Scale (EDSS). We used clinical trial data from the Novartis-Oxford MS database including ~130,000 EDSS assessments from ~8000 patients, spanning all MS phenotypes.</p><p><strong>Results: </strong>Higher brain volume was positively associated with disability improvement at all disability levels (hazard ratio (HR) = 1.09-1.19; 95% credible interval (CI) = 1.02-1.27). Higher T2 lesion volume was negatively associated with disability improvement up to EDSS 6 (HR = 0.80-0.89; 95% CI = 0.75-0.94). Older age, time since first symptoms, and the number of relapses in the past year were confirmed as predictors of future disability worsening.</p><p><strong>Conclusions: </strong>Brain damage was identified as the most consistent factor limiting the patient's probability for improvements from the earliest stages and across the whole course of MS. Protecting brain integrity early in MS should have greater weight in clinical decision-making.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1455-1467"},"PeriodicalIF":4.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241275471","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The long-term disease trajectory of people living with multiple sclerosis (MS) can be improved by initiating efficacious treatment early. More quantitative evidence is needed on factors that affect a patient's risk of disability worsening or possibility of improvement to inform timely treatment decisions.

Methods: We developed a multistate model to quantify the influence of demographic, clinical, and imaging factors on disability worsening and disability improvement simultaneously across the disability spectrum as measured by the Expanded Disability Status Scale (EDSS). We used clinical trial data from the Novartis-Oxford MS database including ~130,000 EDSS assessments from ~8000 patients, spanning all MS phenotypes.

Results: Higher brain volume was positively associated with disability improvement at all disability levels (hazard ratio (HR) = 1.09-1.19; 95% credible interval (CI) = 1.02-1.27). Higher T2 lesion volume was negatively associated with disability improvement up to EDSS 6 (HR = 0.80-0.89; 95% CI = 0.75-0.94). Older age, time since first symptoms, and the number of relapses in the past year were confirmed as predictors of future disability worsening.

Conclusions: Brain damage was identified as the most consistent factor limiting the patient's probability for improvements from the earliest stages and across the whole course of MS. Protecting brain integrity early in MS should have greater weight in clinical decision-making.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用多态模型预测多发性硬化症恶化和好转的因素。
背景:尽早开始有效的治疗可以改善多发性硬化症(MS)患者的长期疾病轨迹。关于影响患者残疾恶化风险或改善可能性的因素,需要更多量化证据,以便为及时治疗决策提供依据:我们建立了一个多州模型,以量化人口学、临床和影像学因素对残疾恶化和残疾改善的影响,这些因素同时影响着以扩展残疾状况量表(EDSS)测量的整个残疾范围。我们使用了诺华-牛津多发性硬化症数据库中的临床试验数据,其中包括来自约8000名患者的约13万次EDSS评估,涵盖了所有多发性硬化症表型:较高的脑容量与所有残疾程度的残疾改善均呈正相关(危险比 (HR) = 1.09-1.19; 95% 可信区间 (CI) = 1.02-1.27)。较高的T2病变体积与EDSS 6的残疾改善呈负相关(HR = 0.80-0.89; 95% CI = 0.75-0.94)。年龄越大、首次出现症状的时间越长、过去一年中复发的次数越多,这些因素都被证实是未来残疾恶化的预测因素:结论:脑损伤被认为是限制多发性硬化症早期和整个病程中患者病情改善可能性的最一致因素。在多发性硬化症的早期阶段保护大脑的完整性应在临床决策中占据更重要的地位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
期刊最新文献
Cryptogenic organising pneumonia in patients treated with ocrelizumab. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Development and initial validation of the Cognitive Change Scale (CCS).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1